These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 39071291)

  • 1. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies.
    Frank S; Persse T; Coleman I; Bankhead A; Li D; De-Sarkar N; Wilson D; Rudoy D; Vashisth M; Galipeau P; Yang M; Hanratty B; Dumpit R; Morrissey C; Corey E; Montgomery RB; Haffner MC; Pritchard C; Vasioukhin V; Ha G; Nelson PS
    bioRxiv; 2024 Jul; ():. PubMed ID: 39071291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
    Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
    Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis of
    Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
    Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
    Dubbury SJ; Boutz PL; Sharp PA
    Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
    Coquan E; Penel N; Lequesne J; Leman R; Lavaud P; Neviere Z; Brachet PE; Meriaux E; Carnot A; Boutrois J; Castera M; Goardon N; Muller E; Leconte A; Thiery-Vuillemin A; Clarisse B; Joly F
    Ther Adv Urol; 2024; 16():17562872241229876. PubMed ID: 38425504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.
    Brown LC; Zhu J; Mauer E; Thiede SN; Macera L; Stein MM; Taxter T; Raghavan D; Burgess EF
    JCO Precis Oncol; 2023 Sep; 7():e2300378. PubMed ID: 38061006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
    Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
    Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
    McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
    Carreira S; Porta N; Arce-Gallego S; Seed G; Llop-Guevara A; Bianchini D; Rescigno P; Paschalis A; Bertan C; Baker C; Goodall J; Miranda S; Riisnaes R; Figueiredo I; Ferreira A; Pereira R; Crespo M; Gurel B; Nava Rodrigues D; Pettitt SJ; Yuan W; Serra V; Rekowski J; Lord CJ; Hall E; Mateo J; de Bono JS
    Cancer Discov; 2021 Nov; 11(11):2812-2827. PubMed ID: 34045297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
    Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
    Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib for the treatment of metastatic prostate cancer.
    Dror CM; Wyatt AW; Chi KN
    Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.
    Zhang G; Lan B; Zhang X; Lin M; Liu Y; Chen J; Guo F
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD51-Mediated DNA Homologous Recombination Is Independent of
    Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
    Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Antonarakis ES; Isaacsson Velho P; Fu W; Wang H; Agarwal N; Sacristan Santos V; Maughan BL; Pili R; Adra N; Sternberg CN; Vlachostergios PJ; Tagawa ST; Bryce AH; McNatty AL; Reichert ZR; Dreicer R; Sartor O; Lotan TL; Hussain M
    JCO Precis Oncol; 2020; 4():370-381. PubMed ID: 32462107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
    Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
    Abida W; Campbell D; Patnaik A; Shapiro JD; Sautois B; Vogelzang NJ; Voog EG; Bryce AH; McDermott R; Ricci F; Rowe J; Zhang J; Piulats JM; Fizazi K; Merseburger AS; Higano CS; Krieger LE; Ryan CJ; Feng FY; Simmons AD; Loehr A; Despain D; Dowson M; Green F; Watkins SP; Golsorkhi T; Chowdhury S
    Clin Cancer Res; 2020 Jun; 26(11):2487-2496. PubMed ID: 32086346
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
    bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.